Clinical Trial Update: Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation trial evaluating Interleukin-7 in combination with Bitherapy in Hepatitis C patients who are resistant to Bitherapy alone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Bitherapy
• Interleukin-7 (interleukin-7)

Snippet

Sponsor: Cytheris SA | Conditions: Hepatitis C | Phase 1, Phase 2 | Status: UNKNOWN